X

Trial Profile

A Phase 1b/2a clinical trial of PIPE-307 in patients with relapsing-remitting multiple sclerosis (RRMS)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PIPE-307 (Primary)
Indications Multiple sclerosis
Focus Adverse reactions

Most Recent Events

13 Dec 2023 According to Contineum Therapeutics media release, Pipeline Therapeutics has changed its name to Contineum Therapeutics
28 Mar 2022 According to a Pipeline Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared IND to initiate this study. The company remains on track to commence patient dosing in mid-2022.
04 Mar 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com